These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17108974)

  • 1. Frontiers in drug discovery.
    Nat Chem Biol; 2006 Dec; 2(12):645. PubMed ID: 17108974
    [No Abstract]   [Full Text] [Related]  

  • 2. RNA interference screening for the discovery of oncology targets.
    Quon K; Kassner PD
    Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of drug discovery for personalized medicine.
    Jain KK
    Curr Opin Mol Ther; 2006 Dec; 8(6):487-92. PubMed ID: 17243483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNAs in drug discovery: target validation and beyond.
    Natt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference as a novel and powerful tool in immunopharmacological research.
    Kong Y; Ruan L; Ma L; Cui Y; Wang JM; Le Y
    Int Immunopharmacol; 2007 Apr; 7(4):417-26. PubMed ID: 17321464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of target validation in drug discovery and development.
    Lowe JA; Jones P; Wilson DM
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):581-4. PubMed ID: 19736617
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens.
    Perrimon N; Friedman A; Mathey-Prevot B; Eggert US
    Drug Discov Today; 2007 Jan; 12(1-2):28-33. PubMed ID: 17198970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemogenomics approaches to novel target discovery.
    Gaither LA
    Expert Rev Proteomics; 2007 Jun; 4(3):411-9. PubMed ID: 17552925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post genomics - from antibody production to small molecule discovery.
    Romano A; McAlpine J; Ecker D
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):166-7. PubMed ID: 18283603
    [No Abstract]   [Full Text] [Related]  

  • 10. Prioritizing hits from phenotypic high-content screens.
    Low J; Stancato L; Lee J; Sutherland JJ
    Curr Opin Drug Discov Devel; 2008 May; 11(3):338-45. PubMed ID: 18428087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomics in drug discovery: the best things come to those who wait.
    Bansal AT; Barnes MR
    Curr Opin Drug Discov Devel; 2008 May; 11(3):303-11. PubMed ID: 18428083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and validation of siRNAs and shRNAs.
    Tilesi F; Fradiani P; Socci V; Willems D; Ascenzioni F
    Curr Opin Mol Ther; 2009 Apr; 11(2):156-64. PubMed ID: 19330721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antisense drug development].
    Funato T; Takeda M
    Tanpakushitsu Kakusan Koso; 2006 Dec; 51(16 Suppl):2515-20. PubMed ID: 17471972
    [No Abstract]   [Full Text] [Related]  

  • 14. [Life driven by RNA].
    Nakamura Y
    Tanpakushitsu Kakusan Koso; 2006 Dec; 51(16 Suppl):2409-12. PubMed ID: 17471955
    [No Abstract]   [Full Text] [Related]  

  • 15. Commercial potential of RNAi.
    Jain KK
    Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of functional RNAs in human diseases].
    Tanaka Y; Kozu T
    Tanpakushitsu Kakusan Koso; 2006 Nov; 51(14 Suppl):2235-7. PubMed ID: 17471945
    [No Abstract]   [Full Text] [Related]  

  • 17. Integrated siRNA design based on surveying of features associated with high RNAi effectiveness.
    Gong W; Ren Y; Xu Q; Wang Y; Lin D; Zhou H; Li T
    BMC Bioinformatics; 2006 Nov; 7():516. PubMed ID: 17129386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroviral microarray-based platform on nanostructured TiO2 for functional genomics and drug discovery.
    Carbone R; Giorgetti L; Zanardi A; Marangi I; Chierici E; Bongiorno G; Fiorentini F; Faretta M; Piseri P; Pelicci PG; Milani P
    Biomaterials; 2007 Apr; 28(13):2244-53. PubMed ID: 17276506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MiRNA in disease and therapeutic development].
    Tanaka Y; Kozu T
    Tanpakushitsu Kakusan Koso; 2006 Dec; 51(16 Suppl):2509-14. PubMed ID: 17471971
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting myostatin for therapies against muscle-wasting disorders.
    Tsuchida K
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):487-94. PubMed ID: 18600566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.